CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Precision BioSciences, Inc. - DTIL CFD

9.6529
2.52%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.2642
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.001
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 9.9029
Open 9.9729
1-Year Change 1448.59%
Day's Range 9.5329 - 9.9729
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 19, 2024 9.6529 -0.3200 -3.21% 9.9729 9.9729 9.5329
Jul 18, 2024 9.9029 -0.1800 -1.79% 10.0829 10.2729 9.6129
Jul 17, 2024 10.2229 0.0900 0.89% 10.1329 10.3229 9.6629
Jul 16, 2024 10.1929 0.0700 0.69% 10.1229 10.3329 9.9729
Jul 15, 2024 10.1429 0.0200 0.20% 10.1229 10.2029 10.0729
Jul 12, 2024 9.9729 0.5100 5.39% 9.4629 10.0129 9.4029
Jul 11, 2024 9.6529 0.0800 0.84% 9.5729 9.7729 9.2129
Jul 10, 2024 9.5729 0.5000 5.51% 9.0729 9.7229 9.0729
Jul 9, 2024 9.1029 -0.0200 -0.22% 9.1229 9.1329 9.0829
Jul 8, 2024 9.1529 0.1000 1.10% 9.0529 9.2629 9.0529
Jul 5, 2024 9.1029 -0.1200 -1.30% 9.2229 9.2229 9.0229
Jul 3, 2024 9.2329 -0.1400 -1.49% 9.3729 9.4529 9.0829
Jul 2, 2024 9.3829 -0.3900 -3.99% 9.7729 9.7729 9.2429
Jul 1, 2024 9.7729 0.2200 2.30% 9.5529 9.8229 9.5529
Jun 28, 2024 9.3429 -0.0700 -0.74% 9.4129 9.4929 9.0829
Jun 27, 2024 9.3929 -0.1900 -1.98% 9.5829 9.7029 9.1229
Jun 26, 2024 9.5029 0.0000 0.00% 9.5029 9.7429 9.4929
Jun 25, 2024 9.4429 0.0900 0.96% 9.3529 9.5829 9.2529
Jun 24, 2024 9.3429 -0.1800 -1.89% 9.5229 9.6129 9.2129
Jun 21, 2024 9.4229 -0.1200 -1.26% 9.5429 9.9029 9.2229

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Precision BioSciences, Inc. Company profile

About Precision BioSciences Inc

Precision BioSciences, Inc is a clinical stage biotechnology company. The Company’s ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. The Company’s pipeline includes Ex vivo Allogeneic CAR T Immunotherapy and In vivo Gene Correction. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. The Company’s subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Precision BioSciences Inc revenues increased from $24.3M to $115.5M. Net loss decreased 72% to $30.6M. Revenues reflect Therapeutics segment increase from $21.9M to $111.7M, Food segment increase of 57% to $3.8M. Lower net loss reflects Therapeutics segment income totaling $32M vs. loss of $50M, Food segment loss decrease of 26% to $3.8M.

Industry: Biotechnology & Medical Research (NEC)

302 E Pettigrew St Ste A100
DURHAM
NORTH CAROLINA 27701-2393
US

People also watch

XRP/USD

0.60 Price
-0.840% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

ETH/USD

3,501.16 Price
-0.750% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

66,943.30 Price
-0.740% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,401.36 Price
-1.830% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 21:00 (UTC)
Spread 1.20

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading